TY - JOUR
T1 - Analysis of GNA13 Protein in Follicular Lymphoma and its Association with Poor Prognosis
AU - Shimono, Joji
AU - Miyoshi, Hiroaki
AU - Yoshida, Noriaki
AU - Kato, Takeharu
AU - Sato, Kensaku
AU - Sugio, Takeshi
AU - Miyawaki, Kohta
AU - Kurita, Daisuke
AU - Sasaki, Yuya
AU - Kawamoto, Keisuke
AU - Imaizumi, Yoshitaka
AU - Kato, Koji
AU - Nagafuji, Koji
AU - Akashi, Koichi
AU - Seto, Masao
AU - Teshima, Takanori
AU - Ohshima, Koichi
N1 - Publisher Copyright:
Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - GNA13 is a G protein involved in modulating tumor proliferative capacity, infiltration, metastasis, and migration. Genomic alteration of GNA13 was frequently observed in follicular lymphoma (FL). In this study, we examined 167 cases of FL by immunostaining of GNA13 using tissue microarray to evaluate the clinical significance. There were 26 GNA13-positive cases (15.6%) and 141 GNA13-negative cases (84.4%). GNA13-positive cases had a higher incidence of early progression of disease for which disease progression was recognized within 2 years compared with GNA13-negative cases (P=0.03). There were no significant differences in other clinicopathologic factors including histological grade, BCL2-IGH translocation, immunohistochemical phenotype, and Follicular Lymphoma International Prognostic Index. In addition, overall survival and progression-free survival were poorer in GNA13-positive cases than in GNA13-negative cases (P=0.009 and 0.005, respectively). In multivariate analysis, GNA13 positivity was found to be a poor prognostic factor for overall survival and progression-free survival. Thus, GNA13 protein expression was an independent prognostic factor and may affect disease progression in FL.
AB - GNA13 is a G protein involved in modulating tumor proliferative capacity, infiltration, metastasis, and migration. Genomic alteration of GNA13 was frequently observed in follicular lymphoma (FL). In this study, we examined 167 cases of FL by immunostaining of GNA13 using tissue microarray to evaluate the clinical significance. There were 26 GNA13-positive cases (15.6%) and 141 GNA13-negative cases (84.4%). GNA13-positive cases had a higher incidence of early progression of disease for which disease progression was recognized within 2 years compared with GNA13-negative cases (P=0.03). There were no significant differences in other clinicopathologic factors including histological grade, BCL2-IGH translocation, immunohistochemical phenotype, and Follicular Lymphoma International Prognostic Index. In addition, overall survival and progression-free survival were poorer in GNA13-positive cases than in GNA13-negative cases (P=0.009 and 0.005, respectively). In multivariate analysis, GNA13 positivity was found to be a poor prognostic factor for overall survival and progression-free survival. Thus, GNA13 protein expression was an independent prognostic factor and may affect disease progression in FL.
UR - http://www.scopus.com/inward/record.url?scp=85054774613&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054774613&partnerID=8YFLogxK
U2 - 10.1097/PAS.0000000000000969
DO - 10.1097/PAS.0000000000000969
M3 - Article
C2 - 30307409
AN - SCOPUS:85054774613
SN - 0147-5185
VL - 42
SP - 1466
EP - 1471
JO - American Journal of Surgical Pathology
JF - American Journal of Surgical Pathology
IS - 11
ER -